JOURNAL ARTICLE
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Add like
Add dislike
Add to saved papers

VH and VL gene usage by anti-beta-amyloid autoantibodies in Alzheimer's disease: detection of highly mutated V regions in both heavy and light chains.

In a previous study, four human IgM kappa monoclonal antibodies (mAbs) secreted by Epstein-Barr-virus-transformed B cell lines independently derived from the peripheral blood of a patient with Alzheimer's disease (AD) were found to react with a conformational epitope of beta-amyloid protein and to stain amyloid plaques in AD brain. Three of these mAbs were studied further. They did not react with an additional panel of antigens and autoantigens. By a competitive inhibition ELISA, the Kd was determined to be 5.7 x 10(-8) M. The VH and V kappa of these mAbs were sequenced at the cDNA level and found to be identical. The corresponding VH and V kappa germline counterpart genes hsigghvm148 and hsiggkvm148 were identified to be analogous to the previous reported VH3 germline gene humighvf1/dp53 and the V kappa IV germline gene hsigk18. DA1/4 and JH4b were used by the heavy chain and J kappa 4 was used by the light chain. Multiple nucleotide substitutions were seen in both VH and V kappa when their sequences were compared to the germline sequences. High replacement/silent ratios in the CDR regions of both VH and V kappa indicate positive-selective pressure. Of a total of 22 amino acid replacements in VH and V kappa, 12 were nonconservative replacements. Furthermore, 7 of these 12 resulted in charge changes. The monoreactivity, the moderately high affinity constant, the clonal expansion evident by identical VH and VL used by these B cells secreting antibodies of interest, and the excessive replacement mutations in both VH and VL segments lead to the conclusion that these antibodies have been generated due to an antigen-driven process.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app